Iatrogenic Cushing's syndrome induced by posaconazole. 2013

Benoit Pilmis, and Hélène Coignard-Biehler, and Vincent Jullien, and Olivier Hermine, and Philippe Touraine, and Marc Lecuit, and Olivier Lortholary
Service de Maladies Infectieuses et Tropicales, Groupe Hospitalier Necker-Enfants Malades, Centre d'Infectiologie Necker-Pasteur, Paris, France.

Iatrogenic Cushing's syndrome is an undesirable outcome of glucocorticoids treatment. It can be increased by pharmacologic interactions. Glucocorticoid therapy, given in association with ritonavir, and some azole treatments are causes of iatrogenic Cushing's syndrome. We present a patient with common-variable immunodeficiency who received 7 years of itraconazole therapy for bronchial colonization with Aspergillus in combination with inhaled fluticasone without any Cushingoid symptoms. After a switch to posaconazole, the patient developed Cushingoid symptoms.

UI MeSH Term Description Entries
D007049 Iatrogenic Disease Any adverse condition in a patient occurring as the result of treatment by a physician, surgeon, or other health professional, especially infections acquired by a patient during the course of treatment. Hospital-Acquired Condition,Condition, Hospital-Acquired,Conditions, Hospital-Acquired,Disease, Iatrogenic,Diseases, Iatrogenic,Hospital Acquired Condition,Hospital-Acquired Conditions,Iatrogenic Diseases
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001980 Bronchi The larger air passages of the lungs arising from the terminal bifurcation of the TRACHEA. They include the largest two primary bronchi which branch out into secondary bronchi, and tertiary bronchi which extend into BRONCHIOLES and PULMONARY ALVEOLI. Primary Bronchi,Primary Bronchus,Secondary Bronchi,Secondary Bronchus,Tertiary Bronchi,Tertiary Bronchus,Bronchi, Primary,Bronchi, Secondary,Bronchi, Tertiary,Bronchus,Bronchus, Primary,Bronchus, Secondary,Bronchus, Tertiary
D001993 Bronchodilator Agents Agents that cause an increase in the expansion of a bronchus or bronchial tubes. Bronchial-Dilating Agents,Bronchodilator,Bronchodilator Agent,Broncholytic Agent,Bronchodilator Effect,Bronchodilator Effects,Bronchodilators,Broncholytic Agents,Broncholytic Effect,Broncholytic Effects,Agent, Bronchodilator,Agent, Broncholytic,Agents, Bronchial-Dilating,Agents, Bronchodilator,Agents, Broncholytic,Bronchial Dilating Agents,Effect, Bronchodilator,Effect, Broncholytic,Effects, Bronchodilator,Effects, Broncholytic
D003480 Cushing Syndrome A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent. Cushing's Syndrome,Hypercortisolism,Syndrome, Cushing,Syndrome, Cushing's
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068298 Fluticasone A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS. Cutivate,Flixonase,Flixotide,Flonase,Flovent,Flovent HFA,Fluticasone Propionate,HFA, Flovent,Propionate, Fluticasone
D000730 Androstadienes Derivatives of the steroid androstane having two double bonds at any site in any of the rings.
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics

Related Publications

Benoit Pilmis, and Hélène Coignard-Biehler, and Vincent Jullien, and Olivier Hermine, and Philippe Touraine, and Marc Lecuit, and Olivier Lortholary
December 1998, Indian pediatrics,
Benoit Pilmis, and Hélène Coignard-Biehler, and Vincent Jullien, and Olivier Hermine, and Philippe Touraine, and Marc Lecuit, and Olivier Lortholary
October 1972, British medical journal,
Benoit Pilmis, and Hélène Coignard-Biehler, and Vincent Jullien, and Olivier Hermine, and Philippe Touraine, and Marc Lecuit, and Olivier Lortholary
June 1976, Minerva pediatrica,
Benoit Pilmis, and Hélène Coignard-Biehler, and Vincent Jullien, and Olivier Hermine, and Philippe Touraine, and Marc Lecuit, and Olivier Lortholary
October 2019, Therapie,
Benoit Pilmis, and Hélène Coignard-Biehler, and Vincent Jullien, and Olivier Hermine, and Philippe Touraine, and Marc Lecuit, and Olivier Lortholary
January 2008, Indian journal of dermatology,
Benoit Pilmis, and Hélène Coignard-Biehler, and Vincent Jullien, and Olivier Hermine, and Philippe Touraine, and Marc Lecuit, and Olivier Lortholary
January 1979, Lancet (London, England),
Benoit Pilmis, and Hélène Coignard-Biehler, and Vincent Jullien, and Olivier Hermine, and Philippe Touraine, and Marc Lecuit, and Olivier Lortholary
December 1980, Revista clinica espanola,
Benoit Pilmis, and Hélène Coignard-Biehler, and Vincent Jullien, and Olivier Hermine, and Philippe Touraine, and Marc Lecuit, and Olivier Lortholary
December 1994, Ophthalmic plastic and reconstructive surgery,
Benoit Pilmis, and Hélène Coignard-Biehler, and Vincent Jullien, and Olivier Hermine, and Philippe Touraine, and Marc Lecuit, and Olivier Lortholary
January 2017, Northern clinics of Istanbul,
Benoit Pilmis, and Hélène Coignard-Biehler, and Vincent Jullien, and Olivier Hermine, and Philippe Touraine, and Marc Lecuit, and Olivier Lortholary
January 2018, Journal of Ayub Medical College, Abbottabad : JAMC,
Copied contents to your clipboard!